Brief: IRLAB Activates All Study Sites In Phase IIb Study Of Pirepemat
31/05/2023 06:24
May 31 (Reuters) - IRLAB Therapeutics AB IRLABa.ST :
* IRLAB HAS ACTIVATED ALL 38 STUDY SITES IN THE PHASE IIB
STUDY OF
PIREPEMAT AIMING TO IMPROVE BALANCE AND REDUCE FALLS IN
PARKINSON’S DISEASE
* PATIENT RECRUITMENT AND RANDOMIZATION ARE EXPECTED TO BE
COMPLETED BY YEAR-END OF 2023
* TOP-LINE RESULTS ARE FURTHER EXPECTED IN H1 2024
Source text for Eikon: ID:nMFNs4cG
Further company coverage: IRLABa.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))